Company (location)

Product

Description

Indication

Status

Date


Celgene Corp. (Summit, N.J.)

Abraxane

Nab-paclitaxel

High-risk early breast cancer patients

Phase III Geparsepto data found a significantly higher DFS rate in patients receiving it compared to those receiving paclitaxel as part of a neoadjuvant treatment regimen (p=0.0044); rates of DFS were 87.1% vs. 80.7% at three years and 83.5% vs. 76.2% at four years, respectively

12/8/17

Daiichi Sankyo Co. Ltd. (Tokyo)

S-8201

HER2-targeting antibody-drug conjugate

Breast cancer

Phase I data of 57 efficacy evaluable patients with HER2-positive metastatic breast cancer pre-treated with Kadcyla showed it produced an overall response rate (ORR) of 61.4% and a disease control rate (DCR) of 94.7%; in the 50 patients who were also pre-treated with Perjeta it produced an ORR of 62% and a DCR of 94%; of the 39 efficacy evaluable patients with hormone-receptor positive disease, it produced an ORR of 56.4% and a DCR of 92.3%; in 19 efficacy evaluable patients with heavily pretreated HER2 low-expressing breast cancer, the ORR was 31.6% and the DCR was 84.2%; in the subgroup of those HER2 low-expressing patients who also had hormone-receptor positive disease, the ORR was 31.3% with a DCR of 87.5%

12/8/17

Puma Biotechnology Inc. (Los Angeles)

Nerlynx

Neratinib

Diarrhea caused by Nerlynx associated with trastuzumab-based adjuvant therapy

Interim results from the phase II CONTROL trial showed of the 137 patients who received the loperamide prophylaxis, 30.7% had grade 3 diarrhea; for the 64 patients taking loperamide plus budesonide, the incidence of grade 3 diarrhea was 26.6%; of the 120 patients who received loperamide plus colestipol, 10.8% had grade 3 diarrhea

12/8/17

Seattle Genetics Inc. (Bothell, Wash.)

Ladiratuz-umab vedotin

Antibody-drug conjugate targeting LIV-1

Metastatic triple-negative breast cancer

Phase I showed an objective response rate of 25%; the clinical benefit rate, which also included patients with stable disease lasting at least 24 weeks, was 28%: the median progression-free survival and median duration of response for 19 patients treated at the recommended dose of 2.5 mg/kg, with a maximum dose of 200 mg per cycle, was 12.1 weeks and 17.4 weeks, respectively

12/8/17


Notes

The date indicated refers to the BioWorld issue in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.

 

No Comments